Thus, the amplification of HER2 is a hallmark of HER2-positive breast cancer that provokes hyperactivation of the signaling pathways, contributing to a more aggressive biological behavior and worse clinical outcomes [115,116]. The gene discussed is ERBB2; the disease is breast carcinoma.